Zoetis Inc. (ZTS) to Issue Quarterly Dividend of $0.53 on June 2nd

Zoetis Inc. (NYSE:ZTS) announced a quarterly dividend on Thursday, February 5th. Stockholders of record on Monday, April 20th will be paid a dividend of 0.53 per share on Tuesday, June 2nd. This represents a c) dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Monday, April 20th.

Zoetis has increased its dividend payment by an average of 0.2%per year over the last three years and has increased its dividend annually for the last 14 consecutive years. Zoetis has a payout ratio of 31.0% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Zoetis to earn $6.75 per share next year, which means the company should continue to be able to cover its $2.12 annual dividend with an expected future payout ratio of 31.4%.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $122.39 on Friday. The stock has a market cap of $51.48 billion, a price-to-earnings ratio of 20.33, a PEG ratio of 1.82 and a beta of 0.98. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. Zoetis has a 12 month low of $113.29 and a 12 month high of $172.23. The stock’s 50 day moving average price is $121.73 and its 200 day moving average price is $126.50.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period last year, the firm earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts anticipate that Zoetis will post 6.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ZTS shares. BTIG Research restated a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research report on Thursday, February 26th. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Leerink Partners restated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. Weiss Ratings lowered shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Finally, Citigroup started coverage on Zoetis in a research report on Wednesday. They set a “buy” rating and a $145.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $152.25.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.